China's Shanghai Pharmaceuticals revenue growth 2022, by category
In 2022, Shanghai Pharmaceutical Group, Co. Ltd. recorded approximately 6.6 percent growth of its overall sales revenue of pharmaceutical products. Among its pharmaceutical product categories, drugs treating respiratory system diseases saw the highest revenue growth of around 16 percent. The enterprise is one of the largest national pharmaceutical groups in China which owns over 1,700 pharmacies.